Outcomes of radiation therapy for resectable M0 gastric cancer

被引:1
|
作者
Gong, Weipeng [1 ]
Zhao, Hongwei [1 ]
Liu, Shanshan [2 ]
Guan, Jie [1 ]
Liu, Xin [1 ]
Hou, Qingsheng [1 ]
Zhu, Zhenyu [1 ]
Guo, Hongliang [1 ]
机构
[1] Shandong Univ, Dept Surg Oncol, Shandong Canc Hosp, Jinan 250117, Shandong, Peoples R China
[2] Shandong Univ, Dept Radiat Oncol, Shandong Canc Hosp, Jinan 250117, Shandong, Peoples R China
关键词
surgery; gastric cancer; radiation therapy; resectable without distant metastases; CHEMORADIOTHERAPY; ADENOCARCINOMA; SURVIVAL; BENEFIT;
D O I
10.18632/oncotarget.22574
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The role of radiaotion therapy in resectable gastric cancer patients without distant metastases remains controversial. This retrospective analysis was performed to identify whether resectable gastric cancer patients without distant metastases might benefit from radiation. Results: The results of the Kaplan-Meier analysis and log-rank test showed that a total of 3309 patients had a MST of 29.0 months, a 1-year survival rate of 74.7%, and a 3-year survival rate of 45.5%. Among them, the MST of the "RPS" group and the "RAS" group were significantly longer compared with that of the "No Radiation" group (32.7vs 32.9 vs 25.3 months, P < 0.05). The 1-year survival rates were 83.7%, 83.5% and 65.6% for the "RPS", "RAS" and "No radiation" groups, respectively (P < 0.05) and the 3-year survival rates were 52.6%, 63.6% and 44.9%, respectively (P < 0.05). The multivariate Cox proportional hazard regression analysis showed that radiation was an independent prognostic factor. Materials and Methods: A total of 5744 patients from the SEER database who were initially diagnosed with histologically confirmed gastric cancer without distant metastases from 2010 to 2013 were included. Patients were divided into three groups as follows: patients who underwent radiation after surgery ("RAS" group), patients who underwent radiation prior to surgery ("RPS" group) and patients who did not undergo radiation, only surgery performed ("No radiation'" group). Conclusions: This retrospective analysis demonstrated that "RPS" or "RAS" alone were independent prognostic factors for survival improvement in selected gastric cancer patients without distant metastases.
引用
收藏
页码:1726 / 1734
页数:9
相关论文
共 50 条
  • [21] M0 Measures for the Walsh System
    François Parreau
    Martine Queffélec
    Journal of Fourier Analysis and Applications, 2009, 15 : 502 - 514
  • [22] Opportunity to observe an M0 transition
    Sheline, R. K.
    Alexa, P.
    JOURNAL OF PHYSICS G-NUCLEAR AND PARTICLE PHYSICS, 2008, 35 (09)
  • [23] M0 Measures for the Walsh System
    Parreau, Francois
    Queffelec, Martine
    JOURNAL OF FOURIER ANALYSIS AND APPLICATIONS, 2009, 15 (04) : 502 - 514
  • [24] Rationality of forms of M0,n
    Hassett, Brendan
    Tschinkel, Yuri
    Zhang, Zhijia
    JOURNAL OF THE LONDON MATHEMATICAL SOCIETY-SECOND SERIES, 2025, 111 (02):
  • [25] Representations on the cohomology of M0,n
    Choi, Jinwon
    Kiem, Young-Hoon
    Lee, Donggun
    ADVANCES IN MATHEMATICS, 2023, 435
  • [26] The role of multimodality treatment in M0 rectal cancer: evidence and research
    Valentini, V.
    Barba, M. C.
    Gambacorta, M. A.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2010, 14 (04) : 334 - 341
  • [27] Outcomes of Postoperative Radiation Therapy in Gastric Cancer from the SEER Database
    Shridhar, R.
    Dombi, G. W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S278 - S279
  • [28] International comparison of androgen-deprivation therapy (ADT) for the treatment of nonmetastatic (M0) prostate cancer (PC).
    Hope, Kirsty
    Graham, Alex
    Arellano, Jorge
    Liede, Alexander
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] Outcomes of preoperative chemoradiation therapy with gemcitabine and accelerated hyperfractionaed radiation for potentially resectable pancreatic cancer
    Nakamori, S
    Nakahira, S
    Miyamoto, A
    Marubashi, S
    Nagano, H
    Dono, K
    Umeshita, K
    Sakon, S
    Monden, M
    ANNALS OF SURGICAL ONCOLOGY, 2005, 12 (02) : S82 - S82
  • [30] Three-Year Outcomes of a Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601)
    Matsuyama, Jin
    Terazawa, Tetsuji
    Goto, Masahiro
    Kawabata, Ryohei
    Endo, Shunji
    Imano, Motohiro
    Fujita, Shoichiro
    Akamaru, Yusuke
    Taniguchi, Hirokazu
    Tatsumi, Mitsutoshi
    Lee, Sang-Woong
    Kawakami, Hisato
    Kurokawa, Yukinori
    Shimokawa, Toshio
    Sakai, Daisuke
    Kato, Takeshi
    Fujitani, Kazumasa
    Satoh, Taroh
    ONCOLOGIST, 2022, 27 (04): : 251 - +